uniQure N.V. Payments to Acquire Intangible Assets
uniQure N.V. (QURE) reported Payments to Acquire Intangible Assets of $2.21 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-27.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireIntangibleAssets · last filed 2023-02-27
- uniQure N.V. payments to acquire intangible assets for the quarter ending 2020-12-31 was -$101.00K.
- uniQure N.V. payments to acquire intangible assets for the quarter ending 2020-09-30 was $100.00K.
- uniQure N.V. payments to acquire intangible assets for the quarter ending 2020-06-30 was $1.00K.
- uniQure N.V. payments to acquire intangible assets for the quarter ending 2020-03-31 was $2.21M, a 122.19% increase year-over-year.
- uniQure N.V. payments to acquire intangible assets for fiscal 2020 was $2.21M, a 122.19% increase from fiscal 2019.
- uniQure N.V. payments to acquire intangible assets for fiscal 2019 was $996.00K, a 46.48% decline from fiscal 2018.
- uniQure N.V. payments to acquire intangible assets for fiscal 2018 was $1.86M, a 65.86% increase from fiscal 2017.
- uniQure N.V. payments to acquire intangible assets for fiscal 2017 was $1.12M, a 40.45% decline from fiscal 2016.
| Period end | Payments to Acquire Intangible Assets 3 month | Payments to Acquire Intangible Assets 6 month | Payments to Acquire Intangible Assets 9 month | Payments to Acquire Intangible Assets 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$101.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$1.00K derived: sum of 2 quarters · filed 2023-02-27 | $0.00 derived: sum of 3 quarters · filed 2023-02-27 | $2.21M 10-K · filed 2023-02-27 |
| 2020-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-25 | $101.00K derived: sum of 2 quarters · filed 2021-10-25 | $2.31M 10-Q · filed 2021-10-25 | $2.31M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-26 | $2.21M 10-Q · filed 2021-07-26 | $2.21M derived: sum of 3 quarters · filed 2022-02-25 | $2.21M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $2.21M 10-Q · filed 2021-05-10 | $2.21M derived: sum of 2 quarters · filed 2022-02-25 | $2.21M derived: sum of 3 quarters · filed 2022-02-25 | $2.21M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $0.00 derived: sum of 2 quarters · filed 2022-02-25 | $0.00 derived: sum of 3 quarters · filed 2022-02-25 | $996.00K 10-K · filed 2022-02-25 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | $0.00 derived: sum of 2 quarters · filed 2020-10-27 | $996.00K 10-Q · filed 2020-10-27 | $1.16M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $996.00K 10-Q · filed 2020-07-30 | $1.16M derived: sum of 3 quarters · filed 2021-03-01 | $1.41M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $996.00K 10-Q · filed 2020-04-29 | $1.16M derived: sum of 2 quarters · filed 2021-03-01 | $1.41M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2018-12-31 | $163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $416.00K derived: sum of 2 quarters · filed 2021-03-01 | $1.86M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $253.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-28 | $1.70M 10-Q · filed 2019-10-28 | ||
| 2018-06-30 | $1.45M 10-Q · filed 2019-07-29 | |||
| 2017-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $544.00K derived: sum of 2 quarters · filed 2020-03-02 | $1.12M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $546.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $1.12M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $578.00K 10-Q · filed 2018-08-08 | |||
| 2016-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $1.88M 10-K · filed 2019-02-28 | ||
| 2016-09-30 | $1.90M 10-Q · filed 2017-11-01 | |||
| 2015-12-31 | $415.00K 10-K · filed 2018-03-14 | |||
| 2014-12-31 | $299.00K 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |